The clinical impact of the classification of carcinoma in situ on tumor recurrence and their clinical course in patients with bladder tumor

Nozomi Hayakawa, Eiji Kikuchi, Shuji Mikami, Kazuhiro Matsumoto, Akira Miyajima, Mototsugu Oya

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To evaluate recurrence and clinical course of bladder carcinoma in situ according to the current carcinoma in situ classification by analyzing the patients with diagnosed carcinoma in situ in our hospital. Methods: Between January 1993 and September 2008, 93 patients were initially diagnosed with bladder carcinoma in situ in our hospital. All specimens underwent an additional review by one uro-pathologist. Primary, secondary and concurrent carcinoma in situ were found in 26, 21 and 46 patients, respectively. Sixty-nine patients (74.2%) underwent bacillus Calmette-Guérin instillation therapy. Results: The multivariate analysis determined that the secondary carcinoma in situ and the absence of bacillus Calmette-Guérin therapy were the independent unfavorable risk factors for tumor recurrence. The 5-year recurrence-free survival rates on primary, concurrent and secondary carcinoma in situ were 60.9, 63.2 and 25.4%, respectively, and the differences between secondary and primary carcinoma in situ, and secondary and concurrent were significant (P= 0.023 and P= 0.006, respectively). During the median follow-up period of 47 months, 19 patients had tumor recurrence in the bladder after the first bacillus Calmette-Guérin therapy, and 13 of them were treated with a second bacillus Calmette-Guérin therapy. After the second bacillus Calmette-Guérin therapy six patients eventually had distant metastasis and three had upper tract recurrence, whereas totally four had a tumor-free status after the second bacillus Calmette-Guérin therapy. Conclusions: The first induction course of bacillus Calmette-Guérin therapy proved to be effective for the prevention of bladder cancer recurrence, however, the efficacy of a second bacillus Calmette-Guérin therapy on a recurrent tumor was somewhat limited.

Original languageEnglish
Article numberhyq228
Pages (from-to)424-429
Number of pages6
JournalJapanese Journal of Clinical Oncology
Volume41
Issue number3
DOIs
Publication statusPublished - 2011 Mar

Fingerprint

Carcinoma in Situ
Urinary Bladder Neoplasms
Bacillus
Recurrence
Neoplasms
Urinary Bladder
Therapeutics
Multivariate Analysis
Survival Rate
Neoplasm Metastasis

Keywords

  • Bacillus Calmette
  • Carcinoma in situ
  • Classification
  • Guérin
  • Progression
  • Recurrence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

The clinical impact of the classification of carcinoma in situ on tumor recurrence and their clinical course in patients with bladder tumor. / Hayakawa, Nozomi; Kikuchi, Eiji; Mikami, Shuji; Matsumoto, Kazuhiro; Miyajima, Akira; Oya, Mototsugu.

In: Japanese Journal of Clinical Oncology, Vol. 41, No. 3, hyq228, 03.2011, p. 424-429.

Research output: Contribution to journalArticle

@article{548af64a18d74c96a64507316653bb1e,
title = "The clinical impact of the classification of carcinoma in situ on tumor recurrence and their clinical course in patients with bladder tumor",
abstract = "Objective: To evaluate recurrence and clinical course of bladder carcinoma in situ according to the current carcinoma in situ classification by analyzing the patients with diagnosed carcinoma in situ in our hospital. Methods: Between January 1993 and September 2008, 93 patients were initially diagnosed with bladder carcinoma in situ in our hospital. All specimens underwent an additional review by one uro-pathologist. Primary, secondary and concurrent carcinoma in situ were found in 26, 21 and 46 patients, respectively. Sixty-nine patients (74.2{\%}) underwent bacillus Calmette-Gu{\'e}rin instillation therapy. Results: The multivariate analysis determined that the secondary carcinoma in situ and the absence of bacillus Calmette-Gu{\'e}rin therapy were the independent unfavorable risk factors for tumor recurrence. The 5-year recurrence-free survival rates on primary, concurrent and secondary carcinoma in situ were 60.9, 63.2 and 25.4{\%}, respectively, and the differences between secondary and primary carcinoma in situ, and secondary and concurrent were significant (P= 0.023 and P= 0.006, respectively). During the median follow-up period of 47 months, 19 patients had tumor recurrence in the bladder after the first bacillus Calmette-Gu{\'e}rin therapy, and 13 of them were treated with a second bacillus Calmette-Gu{\'e}rin therapy. After the second bacillus Calmette-Gu{\'e}rin therapy six patients eventually had distant metastasis and three had upper tract recurrence, whereas totally four had a tumor-free status after the second bacillus Calmette-Gu{\'e}rin therapy. Conclusions: The first induction course of bacillus Calmette-Gu{\'e}rin therapy proved to be effective for the prevention of bladder cancer recurrence, however, the efficacy of a second bacillus Calmette-Gu{\'e}rin therapy on a recurrent tumor was somewhat limited.",
keywords = "Bacillus Calmette, Carcinoma in situ, Classification, Gu{\'e}rin, Progression, Recurrence",
author = "Nozomi Hayakawa and Eiji Kikuchi and Shuji Mikami and Kazuhiro Matsumoto and Akira Miyajima and Mototsugu Oya",
year = "2011",
month = "3",
doi = "10.1093/jjco/hyq228",
language = "English",
volume = "41",
pages = "424--429",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - The clinical impact of the classification of carcinoma in situ on tumor recurrence and their clinical course in patients with bladder tumor

AU - Hayakawa, Nozomi

AU - Kikuchi, Eiji

AU - Mikami, Shuji

AU - Matsumoto, Kazuhiro

AU - Miyajima, Akira

AU - Oya, Mototsugu

PY - 2011/3

Y1 - 2011/3

N2 - Objective: To evaluate recurrence and clinical course of bladder carcinoma in situ according to the current carcinoma in situ classification by analyzing the patients with diagnosed carcinoma in situ in our hospital. Methods: Between January 1993 and September 2008, 93 patients were initially diagnosed with bladder carcinoma in situ in our hospital. All specimens underwent an additional review by one uro-pathologist. Primary, secondary and concurrent carcinoma in situ were found in 26, 21 and 46 patients, respectively. Sixty-nine patients (74.2%) underwent bacillus Calmette-Guérin instillation therapy. Results: The multivariate analysis determined that the secondary carcinoma in situ and the absence of bacillus Calmette-Guérin therapy were the independent unfavorable risk factors for tumor recurrence. The 5-year recurrence-free survival rates on primary, concurrent and secondary carcinoma in situ were 60.9, 63.2 and 25.4%, respectively, and the differences between secondary and primary carcinoma in situ, and secondary and concurrent were significant (P= 0.023 and P= 0.006, respectively). During the median follow-up period of 47 months, 19 patients had tumor recurrence in the bladder after the first bacillus Calmette-Guérin therapy, and 13 of them were treated with a second bacillus Calmette-Guérin therapy. After the second bacillus Calmette-Guérin therapy six patients eventually had distant metastasis and three had upper tract recurrence, whereas totally four had a tumor-free status after the second bacillus Calmette-Guérin therapy. Conclusions: The first induction course of bacillus Calmette-Guérin therapy proved to be effective for the prevention of bladder cancer recurrence, however, the efficacy of a second bacillus Calmette-Guérin therapy on a recurrent tumor was somewhat limited.

AB - Objective: To evaluate recurrence and clinical course of bladder carcinoma in situ according to the current carcinoma in situ classification by analyzing the patients with diagnosed carcinoma in situ in our hospital. Methods: Between January 1993 and September 2008, 93 patients were initially diagnosed with bladder carcinoma in situ in our hospital. All specimens underwent an additional review by one uro-pathologist. Primary, secondary and concurrent carcinoma in situ were found in 26, 21 and 46 patients, respectively. Sixty-nine patients (74.2%) underwent bacillus Calmette-Guérin instillation therapy. Results: The multivariate analysis determined that the secondary carcinoma in situ and the absence of bacillus Calmette-Guérin therapy were the independent unfavorable risk factors for tumor recurrence. The 5-year recurrence-free survival rates on primary, concurrent and secondary carcinoma in situ were 60.9, 63.2 and 25.4%, respectively, and the differences between secondary and primary carcinoma in situ, and secondary and concurrent were significant (P= 0.023 and P= 0.006, respectively). During the median follow-up period of 47 months, 19 patients had tumor recurrence in the bladder after the first bacillus Calmette-Guérin therapy, and 13 of them were treated with a second bacillus Calmette-Guérin therapy. After the second bacillus Calmette-Guérin therapy six patients eventually had distant metastasis and three had upper tract recurrence, whereas totally four had a tumor-free status after the second bacillus Calmette-Guérin therapy. Conclusions: The first induction course of bacillus Calmette-Guérin therapy proved to be effective for the prevention of bladder cancer recurrence, however, the efficacy of a second bacillus Calmette-Guérin therapy on a recurrent tumor was somewhat limited.

KW - Bacillus Calmette

KW - Carcinoma in situ

KW - Classification

KW - Guérin

KW - Progression

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=79952367446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952367446&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyq228

DO - 10.1093/jjco/hyq228

M3 - Article

C2 - 21169349

AN - SCOPUS:79952367446

VL - 41

SP - 424

EP - 429

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 3

M1 - hyq228

ER -